A new HIV-prevention offers hope, but accessibility remains limited

Yeztugo, a brand-name form of Lenacapavir, is a human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP), a form of medication used to reduce the risk of contracting HIV. In June 2025, it received FDA approval and is approximately 99.9% effective. It works by binding to capsid protein subunit interfaces and blocks vital components of the virus’ life cycle, including nuclear import of proviral DNA. Unlike Truvada, a popular form of PrEP, it only requires one injection every six months, compared to a daily pill, allowing for greater peace of mind and a reduced chance of missing a dose. This extended time would especially be useful for people who would have difficulty accessing healthcare consistently or those with inconsistent work schedules. In the red-light district in Mbarara, a city in western Uganda, sex-based tourism is common, with the rate of teenage prostitutes increasing.

This excerpt comes from the named source. Read the original for the full reporting.